Dr. Shambavi Richard welcomes viewers to Cancer Network's FACE-OFF, introducing a debate-driven educational program focused on the evolving role of BCMA-targeted therapies in relapsed/refractory multiple myeloma (R/R MM).
CAR-T vs BCMA Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma Navigating Treatment Selection, Sequencing, and the Evolving BCMA Treatment Landscape
Dr. Prashant Kapoor reviews the pivotal phase 1/2 LINKER-MM1 study evaluating linvoseltamab, a BCMA × CD3 bispecific antibody, in heavily pretreated patients with relapsed/refractory multiple myeloma (R/R MM).
Advertisement
Advertisement
Trending on CancerNetwork
1
Ris-Rez Hits PFS End Point in Phase 3 Osteosarcoma Trial
2
Developing A Precision Approach to CAR T-Cell Toxicity Management
3
RP1's Long Road: A Timeline of RP1's Regulatory Journey in Advanced Melanoma
4
Implementing GU Takeaways From the 2026 ASCO Into Clinical Practice
5